Aardvark Therapeutics

No revenue and negative free cash flow with a pivotal program on voluntary pause substantially reduce predictability. While earlier trials and a recent peer‑reviewed publication support target engagement and hunger reduction signals, the new cardiac signal in healthy volunteers raises uncertainty on dosing, exposure margins and trial timelines.

A first‑mover standard of care further elevates outcome dispersion for future commercial adoption.